Edgewise Therapeutics
Developer of sarcomere modulators for hypertrophic cardiomyopathy and heart failure.
$42.76
After-hours close−0.02 (−0.04%)
At close$42.78(−3.20%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.55 | — | — |
| Aug 2026 | −$0.47 | −$0.53 | −13.3% |
| May 2026 | −$0.50 | −$0.46 | +8.0% |
| Feb 2026 | −$0.43 | −$0.47 | −9.3% |
| Nov 2025 | −$0.40 | −$0.39 | +2.5% |
The latest year is open to everyone — the 22 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Feb 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Feb 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Dec 2020 | |||
| Jun 2020 | |||
| Mar 2020 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 5, 2026 | −$0.55 | — | — | $129.2M | — | — |
| Aug 6, 2026 | −$0.47 | −$0.53 | −13.3% | — | — | — |
| May 7, 2026 | −$0.50 | −$0.46 | +8.0% | — | — | — |
| Feb 26, 2026 | −$0.43 | −$0.47 | −9.3% | — | — | — |
| Nov 6, 2025 | −$0.40 | −$0.39 | +2.5% | — | — | — |
The latest year is open to everyone — the 22 quarters behind it read with an account. Sign in | ||||||
| Aug 7, 2025 | ||||||
| May 8, 2025 | ||||||
| Mar 3, 2025 | ||||||
| Nov 7, 2024 | ||||||
| Aug 8, 2024 | ||||||
| May 9, 2024 | ||||||
| Feb 22, 2024 | ||||||
| Nov 9, 2023 | ||||||
| Aug 10, 2023 | ||||||
| May 11, 2023 | ||||||
| Feb 23, 2023 | ||||||
| Nov 3, 2022 | ||||||
| Aug 4, 2022 | ||||||
| May 11, 2022 | ||||||
| Feb 24, 2022 | ||||||
| Nov 10, 2021 | ||||||
| Aug 9, 2021 | ||||||
| May 13, 2021 | ||||||
| Mar 26, 2021 | ||||||
| Dec 31, 2020 | ||||||
| Jun 30, 2020 | ||||||
| Mar 31, 2020 | ||||||